Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 7/20 | 0.64 |
| ▸ | ACHE | P22303 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516120 | 1.00 | PTGIR (0.72) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL17346623 | 0.94 | PTGIR (0.81) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL17407562 | 0.86 | PTGIR (0.70) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL1118700 | 0.84 | PTGIR (1.00) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL1118698 | 0.84 | PTGIR (1.00) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL30444339 | 0.78 | NR1H4 (0.64) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL11466967 | 0.78 | PTGIR (0.59) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL12407172 | 0.78 | PTGIR (0.59) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL12107278 | 0.78 | PTGIR (0.59) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL27928039 | 0.78 | PTGIR (0.59) | PTGIRBCHEACHEMAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50267-E1 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2857015-B1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200375930-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2280696-B9 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-2857015-A1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2280696-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4266/4885ACHE 4288/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | PTGIR 1/4885BCHE 4660/4885ACHE 4778/4885 |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4252/4885ACHE 4274/4885 |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PLOD3 | PTGIR 1/4885BCHE 4413/4885ACHE 4335/4885 |
| US-20200375930-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4252/4885ACHE 4274/4885 |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4252/4885ACHE 4274/4885 |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4252/4885ACHE 4274/4885 |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4250/4885ACHE 4290/4885 |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | PTGIR 1/4885BCHE 4266/4885ACHE 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.